All News

Covid lung pneumonia corona (keep)

Clinical Trial Boom or Bust in Severe COVID-19

Jack Cush, MD

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Jack Cush, MD

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
URI.infection.COrona.jpg

COVID Transmission from Young to Old

Jack Cush, MD

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.

Read Article
DVT.PE_.Blood_.jpg

Tofacitinib and Thromboembolic Risk

Jack Cush, MD

Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m

Read Article
Clot.DVT_.VTE_.blood_.jpg

Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity

Jack Cush, MD

A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA)  and that risk is linked to RA disease activity. 

Read Article
steroids.prednisone.pills_.jpg

Systemic Steroids Reduce Mortality in COVID-19

Jack Cush, MD

JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.

Read Article
ild.jpg

Slow Lung Decline Typical in Systemic Sclerosis

RheumNow

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database foun

Read Article
podcast logo

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article
heart-665185__180.jpg

Ustekinumab Early Risk for Cardiovascular Events

Jack Cush, MD

JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.

Read Article
What do you do with pharmacist drug alert for antimalarial cardiac safety &/or drug interactions @RheumNow #ACR2020 @CRASCRRheum

Janet Pope Janetbirdope ( View Tweet)

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat

Links:

Peter Nash drpnash ( View Tweet)

Swedish population studied CV risk, studied gout. Among 22,057, 910 (4.1%) developed incident gout by 27.5 yrs w/ 5 Clusters: C1 no/few comorb; C2 had CKD; C3 CV dz; C4 obesity, dyslipidemia; C5 DM, HTN, diuretics. 86% of incident gout came from C1 & C4 https://t.co/TeMdXx5qU1

Links:

Dr. John Cush RheumNow ( View Tweet)

EUSTAR study of ILD in systemic sclerosis: 826 pts with SSc-ILD finds 27% with progressive ILD (mod-severe FVC decline >5-10%) over 12 mos. Predictive factors for FVC decline over 5 yrs were male sex, higher mRSS skin score and reflux/dysphagia symptoms. https://t.co/lLd2FrMIkx

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 196 RA pts shows lung Dz common by chest CT, regardless of serostatus. RA lung=higher mortality (HR of 5.3). RA lung dz found in 28%; 16% had ILD, 14% bronchiectasis, 9.5% w pleural dz. RA lung dz in both seropositive (29%) & seronegative (28%) https://t.co/upNX7cvlWq

Links:

Dr. John Cush RheumNow ( View Tweet)

European collaborative study of eosinophilic granulomatosis with polyangiitis (EGPA) Rx w/ RTX, mepolizumab or omalizumab (OMA). MEP > RTX > OMA. Mepolizumab was highly effective in GC‐dependent asthma. https://t.co/fi8pjnJO03

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80) https://t.co/yIRubED6VX

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish comparison of 15K RA, 301K Diabetes adn 75K gen population; RA assoc w/ increased risk of CHF (HR 1.51), MI (HR 1.58), stroke (HR 1.22) vs gen. population; but RA had 20-40% lower CHF/MI/CVA than diabetes pts (who had highest 10 yr mortality). https://t.co/R20EUPAlML

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more. Watch here>> https://t.co/cBHTeUQhff or liste to podcast here> https://t.co/KBgmsoGRzU or on iTunes> https://t.co/FHJv01AAbC

Links:

Dr. John Cush RheumNow ( View Tweet)

High-risk coronary plaques (LRNC) assessed by Coronary CT scores in 209 biologic naive Psoriasis pts. LNRC correlated w/ Framingham risk & Dz activity. After 1 year those on biologics had signif reduction in LRNC, but those not on biologics had no change https://t.co/8o74pjIs5n

Links:

Dr. John Cush RheumNow ( View Tweet)

Cluster analysis of 168 antiphospholipid pts shows that having arterial thromboses and cardiovascular risk factors was associated with mortality and poorest prognosis in APS. https://t.co/Nb7lZNu4jT

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×